Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

BMS-777607

A potent Met kinase superfamily inhibitor
Catalog #: 2455
SKU-Size Size Price Qty
2455-5 5 mg
$125.00
2455-25 25 mg
$475.00
More Sizes Get Quote

Product Details

Alternate Name N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
Appearance White to off-white solid
CAS # 1025720-94-8
Molecular Formula C₂₅H₁₉ClF₂N₄O₄
Molecular Weight 512.89
Purity ≥98% by HPLC
Solubility DMSO (>40 mg/ml)
SMILES CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F
InChi InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)
InChi Key VNBRGSXVFBYQNN-UHFFFAOYSA-N
PubChem CID 24794418
Handling Protect from air and light
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

A potent, selective and ATP-competitive Met kinase superfamily inhibitor (IC₅₀ = 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM for c-Met, Axl, RON, and Tyro-3, respectively). it was >40-fold selective for Met kinase family targets versus Lck, VEGFR-2, and TrkA/B and > 500-fold selective versus all other receptor and non-receptor kinases.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.